Clinical Commander

Back to dossier
neuro.rcvs.v1PRODUCTION
neuro.rcvs.v1

Reversible Cerebral Vasoconstriction Syndrome (RCVS / Call-Fleming)

neurologyacutesubacuteadultpregnancy
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult (or postpartum) patient with recurrent thunderclap headache (or single thunderclap with vasoconstrictive trigger / cortical SAH / watershed infarct); RCVS diagnostic framework requires reversibility on follow-up imaging at 6-12 wk (Calabrese Ann Intern Med 2007 PMID 17200220)

Inputs
0
Actions
0
Advance rule
Set
Advance when

RCVS clinically suspected on thunderclap-headache phenotype

Patient inputs (17)

Reproductive-to-middle-age predominant; mean 42 y (Singhal Arch Neurol 2011 PMID 21482916; Ducros Brain 2007 PMID 18025032)

Female 75-81% predominance; postpartum 4-12 wk window is a high-incidence trigger (Singhal 2011 PMID 21482916; Calabrese 2007 PMID 17200220)

Identify postpartum-RCVS phenotype + exclude eclampsia overlay (Ducros 2007 PMID 18025032 — postpartum 5/67)

SSRIs / SNRIs / triptans / ergots / nasal decongestants / pseudoephedrine / MDMA / cocaine / cannabis / TCAs — DISCONTINUE on RCVS suspicion (Calabrese 2007 PMID 17200220; Singhal 2011 PMID 21482916 — 42% had vasoconstrictive-drug exposure)

CT/MRI brain to rule SAH / ICH / infarct + look for convexity SAH / watershed infarct / PRES overlay; initial brain imaging normal in 55% (Singhal 2011 PMID 21482916)

CTA / MRA / DSA for "string-and-beads" segmental multifocal vasoconstriction — diagnostic anchor (Calabrese 2007 PMID 17200220); MRA may miss early distal-vessel involvement — DSA is gold standard when high suspicion + non-invasive negative

Baseline + screen for sympathomimetic-drug-induced thrombocytopenia / coagulopathy / postpartum HELLP overlay

Baseline coags pre-LP and to inform anticoagulation contraindication in convexity-SAH or ICH RCVS-complication phenotypes

Baseline eGFR; nimodipine extensively hepatic-metabolised (not renal-dose-adjusted) but renal panel informs antihypertensive selection / contrast safety

Mental-status decline triggers ICU + repeat imaging; catastrophic RCVS with massive edema/ICH is rare but devastating (Ducros 2012 PMID 22995694)

BP control informs treatment — but AVOID hypotension (perfusion-pressure-dependent vasoconstricted territories may infarct on aggressive lowering); also screen for postpartum HTN / eclampsia overlay (Ducros 2012 PMID 22995694)

MRV gradient-echo to exclude CVT in postpartum / OCP / thrombophilia thunderclap-headache patient (Ducros 2012 PMID 22995694; per neuro.cerebral-venous-thrombosis.v1)

Catecholamine-secreting tumour (pheochromocytoma / paraganglioma) is a rare but reversible RCVS trigger — screen if hypertensive / paroxysmal symptoms (Calabrese 2007 PMID 17200220)

Cocaine, amphetamine, cannabis, MDMA, ergotamines are major RCVS triggers; Ducros 2007 (PMID 18025032) — 37/67 had vasoactive substance exposure (cannabis, SSRIs, decongestants predominant)

Erythropoietin, IVIG, tacrolimus, cyclosporine, intra-arterial contrast and recent blood-product transfusion are recognised RCVS triggers (Calabrese 2007 PMID 17200220)

Prior migraine present in ≈40% of RCVS cohorts — but migraine alone does NOT diagnose RCVS and triptan use during RCVS can precipitate strokes (Singhal 2011 PMID 21482916 — 40% prior migraine)

Baseline LFT — nimodipine hepatic metabolism + monitor for hepatic-impairment dose reduction (Ducros 2012 PMID 22995694)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (10)

10 need judgement
  • informationallife_threateninglarge_lobar_ich_complicating_rcvs
    Lobar intracerebral hemorrhage on CT/MRI complicating RCVS (Ducros 2007 PMID 18025032 — 6%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningextensive_watershed_or_posterior_circulation_ischemic_stroke
    Extensive watershed / cortical / posterior-circulation ischemic stroke (Ducros 2007 PMID 18025032 — 4% infarction, typically week 2)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstatus_epilepticus_during_rcvs
    Status epilepticus complicating RCVS (Ducros 2007 PMID 18025032 — seizures 3%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepostpartum_rcvs_with_eclampsia_overlay
    Postpartum 4-12 wk RCVS with eclampsia features (HTN + proteinuria + edema + new seizure) (Ducros 2012 PMID 22995694)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereglucocorticoid_pre_exposure
    Patient pre-treated with glucocorticoids for presumed PACNS / migraine / other dx before RCVS confirmed (Singhal Neurology 2017 PMID 27940651)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepersistent_vasoconstriction_at_12_weeks
    Repeat MRA at 12 wk shows persistent multifocal vasoconstriction without resolution — atypical for RCVS (Calabrese 2007 PMID 17200220)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateconcurrent_pres_overlay
    PRES findings (posterior parieto-occipital edema on MRI FLAIR) co-existing with RCVS (Ducros 2007 PMID 18025032 — 9%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterecurrent_rcvs
    Recurrent RCVS episode after prior confirmed RCVS resolution — incidence ≈5% (Ducros 2012 PMID 22995694)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateparoxysmal_htn_with_thunderclap_headache
    Paroxysmal HTN crises + diaphoresis + palpitations during RCVS course (Calabrese 2007 PMID 17200220)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatercvs_score_ambiguous_3_to_4
    RCVSscore 3-4 (intermediate) — not definitively RCVS or PACNS (Rocha 2019 PMID 30635475)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives risk stratification
Loading…

Recommended regimen

RCVS calcium-channel-blocker + trigger-removal + supportive-care ladder (Calabrese Ann Intern Med 2007 PMID 17200220 + Ducros Lancet Neurol 2012 PMID 22995694 + Singhal Neurology 2017 PMID 27940651 anti-steroid pivot)
axis: rcvs_vasodilator_bundlestep 1 - Step 1 — TRIGGER REMOVAL (non-pharmacologic but the single most important intervention) (Calabrese 2007 PMID 17200220; Singhal 2011 PMID 21482916)
Selected step "Step 1 — TRIGGER REMOVAL (non-pharmacologic but the single most important intervention) (Calabrese 2007 PMID 17200220; Singhal 2011 PMID 21482916)" — RCVS suspected — sympathomimetic / serotonergic / vasoactive substance exposure identified
  • discontinue_ssri_snri_triptan_ergot_decongestant_sympathomimetic
    first line
    lifestyle_trigger_removal
    triggers: SSRI_SNRI_exposure, triptan_exposure, ergot_exposure, nasal_decongestant_exposure, cocaine_amphetamine_cannabis_MDMA_exposure
    Vasoactive trigger removal is the foundational RCVS treatment — 42% of Singhal 2011 cohort (PMID 21482916) and 55% of Ducros 2007 series (PMID 18025032) had identifiable drug triggers; recurrence linked to re-exposure

outpatient playbook — drug actions (1)

  1. 1. nimodipine taper
    rxcui 7426
    Taper from 60 mg q4h over 1-2 wk once headache resolved and MRA normalises • PO • tapering schedule
    trigger: Reversibility confirmed on repeat MRA at 6-12 wk
    Discontinue CCB once disease has self-resolved (typically 1-3 mo per Calabrese 2007 PMID 17200220)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recurrent thunderclap headache (peak <1 min, severe, ≥2 episodes over 1-3 wk) — pathognomonic RCVS entry (Ducros Lancet Neurol 2012 PMID 22995694; Ducros Brain 2007 PMID 18025032 — 94% present with multiple thunderclaps); Thunderclap headache provoked by Valsalva / sexual activity / exercise / bathing / sympathomimetic drug ingestion (Calabrese Ann Intern Med 2007 PMID 17200220); Thunderclap headache 4-12 wk postpartum — postpartum cerebral angiopathy / RCVS phenotype (Calabrese 2007 PMID 17200220; Ducros 2012 PMID 22995694).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Reversible Cerebral Vasoconstriction Syndrome (RCVS / Call-Fleming)** (neuro.rcvs.v1).
Phenotype framing: RCVS (recurrent thunderclap + reversible multifocal beading + normal CSF) vs aneurysmal SAH (cisternal blood + aneurysm) vs CVT (MRV defect) vs PRES (parenchymal posterior edema — frequent OVERLAP ~10-30%) vs PACNS (insidious onset + CSF pleocytosis + biopsy + NOT reversible) vs intracranial atherosclerosis (older + smooth concentric narrowing) vs fibromuscular dysplasia vs cervical artery dissection vs migraine with prolonged aura (Calabrese 2007 PMID 17200220; Rocha 2019 PMID 30635475)
Scope: Adult (or postpartum) patient with recurrent thunderclap headache (or single thunderclap with vasoconstrictive trigger / cortical SAH / watershed infarct); RCVS diagnostic framework requires reversibility on follow-up imaging at 6-12 wk (Calabrese Ann Intern Med 2007 PMID 17200220)

No severity triggers fired against current inputs.

Plan

Regimen axis: **RCVS calcium-channel-blocker + trigger-removal + supportive-care ladder (Calabrese Ann Intern Med 2007 PMID 17200220 + Ducros Lancet Neurol 2012 PMID 22995694 + Singhal Neurology 2017 PMID 27940651 anti-steroid pivot)** — step "Step 1 — TRIGGER REMOVAL (non-pharmacologic but the single most important intervention) (Calabrese 2007 PMID 17200220; Singhal 2011 PMID 21482916)".
1. discontinue_ssri_snri_triptan_ergot_decongestant_sympathomimetic (lifestyle_trigger_removal, first line) — Vasoactive trigger removal is the foundational RCVS treatment — 42% of Singhal 2011 cohort (PMID 21482916) and 55% of Ducros 2007 series (PMID 18025032) had identifiable drug triggers; recurrence linked to re-exposure

Setting playbook (outpatient) — Confirm reversibility on repeat MRA at 6-12 wk (diagnostic gold standard per Calabrese 2007 PMID 17200220), taper and discontinue nimodipine, counsel re: lifelong trigger avoidance, future-pregnancy postpartum-RCVS recurrence (~5%) and contraception choice, screen for residual neurocognitive sequelae
2. nimodipine taper Taper from 60 mg q4h over 1-2 wk once headache resolved and MRA normalises PO tapering schedule — Reversibility confirmed on repeat MRA at 6-12 wk (Discontinue CCB once disease has self-resolved (typically 1-3 mo per Calabrese 2007 PMID 17200220))

Non-pharmacologic actions:
- Trigger-avoidance counselling — written list of vasoactive substances to avoid lifelong (Calabrese 2007 PMID 17200220)
- Return precautions — any new thunderclap headache / focal deficit / new seizure → ED immediately
- Driving evaluation per local regulation if seizure history
- Smoking and cannabis cessation reinforcement

AVOID / contraindication checks:
- No_glucocorticoids_in_confirmed_RCVS (Singhal Neurology 2017 PMID 27940651 — independent predictor of worsening + poor mRS)
- No_triptans_or_ergots_during_RCVS_phase (Calabrese 2007 PMID 17200220)
- No_sympathomimetic_decongestants_pseudoephedrine_phenylephrine (Calabrese 2007 PMID 17200220)
- No_aggressive_BP_lowering_below_MAP_70_vasoconstricted_territories_perfusion_dependent (Ducros 2012 PMID 22995694)
- No_systemic_tPA_in_RCVS_complicated_ischemic_stroke_without_first_securing_diagnosis (Calabrese 2007 PMID 17200220)
- Caution_verapamil_diltiazem_with_AV_block_or_HFrEF (general CCB pharmacology)

Monitoring

Regimen monitoring:
- SBP / HR q4h during nimodipine initiation; hold dose if SBP <100 mm Hg
- Daily neuro-checks during acute admission (Ducros 2012 PMID 22995694)
- Headache diary throughout outpatient phase
- Repeat MRA at 6-12 wk to confirm reversibility (diagnostic gold standard per Calabrese 2007 PMID 17200220)
- LFT at baseline + 4 wk on nimodipine (hepatic metabolism — Ducros 2012 PMID 22995694)

Setting (outpatient) monitoring:
- Follow-up at 6-12 wk for repeat MRA
- Headache-clinic / vascular-neurology referral at 3 mo if persistent symptoms
- Annual neurology follow-up × 2 y for recurrence surveillance

Follow-up plan: Headache clinic / vascular neurology at 6-12 wk for repeat MRA (reversibility = diagnostic gold standard); discontinue nimodipine when angiogram normalises and headache resolves (typically 1-3 mo); LIFELONG avoidance of SSRIs/triptans/sympathomimetics during high-risk windows; counsel re: future-pregnancy postpartum-RCVS recurrence; recurrence ≈5% (Ducros 2012 PMID 22995694; Singhal 2011 PMID 21482916)
- Close-out criterion: Reversibility confirmed + trigger avoidance plan documented + recurrence counselling complete

Monitoring phase: Daily neuro-checks during inpatient phase; nimodipine BP / HR monitoring (caution if SBP<120); repeat MRA at 6-12 wk to confirm reversibility (gold-standard diagnostic confirmation per Calabrese 2007 PMID 17200220); headache diary; if late ischemic stroke (typical week 2 timing per Ducros 2007 PMID 18025032) → re-image + escalate

Disposition

Current setting: outpatient — Confirm reversibility on repeat MRA at 6-12 wk (diagnostic gold standard per Calabrese 2007 PMID 17200220), taper and discontinue nimodipine, counsel re: lifelong trigger avoidance, future-pregnancy postpartum-RCVS recurrence (~5%) and contraception choice, screen for residual neurocognitive sequelae

Disposition criteria:
- Reversibility confirmed + nimodipine tapered + trigger-avoidance plan documented → discharge from acute follow-up; annual surveillance × 2 y

Escalation triggers (move to higher acuity):
- New thunderclap headache → ED (recurrent RCVS ≈5% — Ducros 2012 PMID 22995694)
- New focal deficit → ED
- Persistent vasoconstriction at 12 wk MRA → reconsider PACNS / FMD / other vasculopathy diagnosis (Rocha 2019 PMID 30635475)

Patient Action Plan

**RCVS recurrence-prevention + trigger-avoidance action plan**
Personalised values: nimodipine_taper_schedule, next_MRA_date, identified_trigger_list, pregnancy_postpartum_status, baseline_neuro_function.

**Doing well — headaches resolving on nimodipine + trigger avoidance** (green):
Triggers:
- no_new_thunderclap_headache
- no_focal_deficit
- no_new_seizure
- tolerating_nimodipine
Actions:
- Continue nimodipine as prescribed
- Keep MRA + headache-clinic appointments
- Avoid SSRIs / triptans / decongestants / sympathomimetics / cannabis / cocaine / MDMA
- Call clinic FIRST if planning pregnancy (postpartum recurrence ~5%)

**Caution — call clinic same day** (yellow):
Triggers:
- new_persistent_headache_>24h_different_from_baseline
- mild_BP_drop_<100_on_nimodipine
- missed_doses
- planned_dental_or_surgery_requiring_anesthesia
Actions:
- Call clinic same day
- Do NOT stop nimodipine without instruction
- Bring medication list to call

**Emergency — call 911 / go to ED** (red):
Triggers:
- new_thunderclap_headache
- new_weakness_speech_difficulty_visual_loss
- new_seizure
- loss_of_consciousness
- persistent_vomiting_severe_headache
Actions:
- Call 911 / go to nearest ED
- Tell ED you have RCVS and take nimodipine
- AVOID triptans / ergots / steroids — show ED this card
Contact provider when:
- Any red-zone trigger
- After any ED visit so vascular-neurology team updated

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Lobar intracerebral hemorrhage on CT/MRI complicating RCVS (Ducros 2007 PMID 18025032 — 6%)
- [LIFE_THREATENING] Extensive watershed / cortical / posterior-circulation ischemic stroke (Ducros 2007 PMID 18025032 — 4% infarction, typically week 2)
- [LIFE_THREATENING] Status epilepticus complicating RCVS (Ducros 2007 PMID 18025032 — seizures 3%)

Citations

- Calabrese et al, Ann Intern Med 2007 (foundational diagnostic framework) + Ducros, Lancet Neurol 2012 (comprehensive review) + Singhal Neurology 2017 (glucocorticoid-avoidance anchor) + Rocha Neurology 2019 (RCVSscore for PACNS differentiation) [PMID:17200220](https://pubmed.ncbi.nlm.nih.gov/17200220/)
- Cited evidence (PMID 22995694) [PMID:22995694](https://pubmed.ncbi.nlm.nih.gov/22995694/)
- Cited evidence (PMID 18025032) [PMID:18025032](https://pubmed.ncbi.nlm.nih.gov/18025032/)
- Cited evidence (PMID 21482916) [PMID:21482916](https://pubmed.ncbi.nlm.nih.gov/21482916/)
- Cited evidence (PMID 27940651) [PMID:27940651](https://pubmed.ncbi.nlm.nih.gov/27940651/)

Last reconciled with current guidelines: 2026-05-26.
References
  • Calabrese et al, Ann Intern Med 2007 (foundational diagnostic framework) + Ducros, Lancet Neurol 2012 (comprehensive review) + Singhal Neurology 2017 (glucocorticoid-avoidance anchor) + Rocha Neurology 2019 (RCVSscore for PACNS differentiation) — PMID:17200220
  • Cited evidence (PMID 22995694) — PMID:22995694
  • Cited evidence (PMID 18025032) — PMID:18025032
  • Cited evidence (PMID 21482916) — PMID:21482916
  • Cited evidence (PMID 27940651) — PMID:27940651